Annovis Bio’s Alzheimer’s Drug Shows Promise in Phase II/III Trial
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced promising results from its recent Phase II/III clinical trial for its lead drug candidate, Buntanetap, targeting Alzheimer’s disease (AD). The …
Annovis Bio’s Alzheimer’s Drug Shows Promise in Phase II/III Trial Read More